Point72 Asset Management’s AbCellera Biologics ABCL Stock Holding History

Point72 Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.01M	Buy	1,149,325 +172,818	+18%	+$622K	0.01%	1858
2025 Q4	$3.34M	Buy	+976,507	New	+$4.36M	﹤0.01%	2128
2023 Q3	–	Sell	-3,959	Closed	-$25.6K	–	2407
2023 Q2	$25.6K	Buy	+3,959	New	+$27K	﹤0.01%	1743
2021 Q4	–	Sell	-272,984	Closed	-$5.47M	–	1059
2021 Q3	$5.47M	Buy	+272,984	New	+$4.83M	0.02%	643
2021 Q1	–	Sell	-55,000	Closed	-$2.21M	–	930
2020 Q4	$2.21M	Buy	+55,000	New	+$2.52M	0.01%	715

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management's ABCL Position: Q1 2026 in Review

Point72 Asset Management increased its AbCellera Biologics (ABCL) stake by 18% in Q1 2026, buying an estimated $622K and bringing the position to 1,149,325 shares worth $4.01M. The position accounts for 0.01% of the portfolio, ranked #1858.

Point72 Asset Management first reported a position in ABCL in Q4 2020 and has held it in 5 quarters since. The position peaked at $5.47M in Q3 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Point72 Asset Management held 1,149,325 shares of AbCellera Biologics worth $4.01M as of Q1 2026.
Point72 Asset Management bought 172,818 AbCellera Biologics shares in Q1 2026, an estimated $622K.
AbCellera Biologics made up 0.01% of Point72 Asset Management's portfolio in Q1 2026, its #1858 holding.
Point72 Asset Management first reported a position in AbCellera Biologics in Q4 2020 and has held it in 5 quarters since.
Point72 Asset Management's AbCellera Biologics position peaked at $5.47M in Q3 2021.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.